MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-08-2022
Albireo Pharma ROE Ratio 2011-2026 | ALBO
Annual ROE Ratio Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -19.38 | -59.39 | -67.32 | -37.6 | -37.41 | -52.03 | -47.37 | -61.99 | -59.38 | -66.89 | -28.57 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -19.38 | -67.32 | -48.85 |
Quarterly ROE Ratio Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -101.55 | -70.14 | -0.95 | 2.11 | -30.24 | -47.2 | -95.58 | -74.86 | -45.71 | -69.22 | -75.78 | -82.26 | -59.25 | -70.68 | -58.6 | -52.66 | -24.67 | -34.64 | -33.19 | -30.74 | -29.67 | -40.57 | -41.5 | -26.25 | -13.88 | 22.9 | -5.39 | -27.52 | -30.7 | 134.02 | 121.26 | 123.54 | 110.66 | -98.87 | -49.41 | -94.73 | -77.41 | -81.21 | -97.66 | -105.18 | -110.83 | -112.46 | -82.36 | -486.87 | -487.18 | 11.15 | -471.4 | -13.46 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 134.02 | -487.18 | -64.93 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Immatics N.V.
IMTX
|
1.79 | $ 9.4 | -1.16 % | $ 591 M |  Germany |
 |
Incyte Corporation
INCY
|
24.9 | $ 90.47 | 0.02 % | $ 17.7 B |  USA |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M | Germany |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Aileron Therapeutics
ALRN
|
-115.61 | - | 10.36 % | $ 9.8 M | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 215.49 | -1.18 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 19.43 | 1.04 % | $ 908 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
CytomX Therapeutics
CTMX
|
-17.54 | $ 4.19 | -5.95 % | $ 578 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-123.35 | $ 0.72 | 18.96 % | $ 8.25 M |  Israel |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Exelixis
EXEL
|
36.21 | $ 41.39 | -0.05 % | $ 11.2 B | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.35 | -3.57 % | $ 344 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
ChemoCentryx
CCXI
|
-46.05 | - | - | $ 3.74 B | USA |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.59 | -1.52 % | $ 16.3 M | USA |
 |
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-43.75 | $ 4.29 | -3.05 % | $ 822 M | Canada |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
-46.9 | $ 69.54 | -1.77 % | $ 11.1 B | USA |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Calithera Biosciences
CALA
|
-1373.04 | - | -10.95 % | $ 876 K | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Cara Therapeutics
CARA
|
-207.61 | - | -3.03 % | $ 260 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
18.24 | $ 27.01 | -2.14 % | $ 1.55 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |